➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
McKinsey
Dow
Johnson and Johnson
Moodys

Last Updated: August 12, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,987,264

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,987,264
Title:Method and composition for treating a serotonin receptor-mediated condition
Abstract: A method and composition for treating serotonin receptor-mediated conditions.
Inventor(s): Polymeropoulos; Mihael H. (Potomac, MD), Baroldi; Paolo (Potomac, MD), Wolfgang; Curt (Germantown, MD)
Assignee: Vanda Pharmaceuticals Inc. (Washington, DC)
Application Number:15/242,468
Patent Claims:1. A method of antagonizing a 5-HT.sub.2A receptor in an animal, the method comprising: internally administering to the animal an effective amount of 4-[3-[4-(6-fluoro-1,2,-benzisoxazol-3-yl)-1-piperidinyl]propoxy- ]-3-methoxy-benzoic acid or pharmaceutically-acceptable salt thereof.

2. The method of claim 1, wherein the 5-HT.sub.2A receptor is not located in the brain.

3. The method of claim 1, wherein the 4-[3-[4-(6-fluoro-1,2,-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methox- y-benzoic acid or pharmaceutically-acceptable salt thereof administered to the animal is between about 1 mg/day and about 500 mg/day.

4. The method of claim 3, wherein the effective amount is between about 5 mg/day and about 100 mg/day.

5. The method of claim 1, wherein the effective amount of 4-[3-[4-(6-fluoro-1,2,-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methox- y-benzoic acid or pharmaceutically-acceptable salt thereof administered to the animal is between about 0.01 mg/kg/day and about 10 mg/kg/day.

6. The method of claim 5, wherein the effective amount is between about 0.5 mg/kg/day and about 1.5 mg/kg/day.

7. The method of claim 1, wherein the animal is a human.

8. A method of antagonizing a 5-HT.sub.2A receptor in an animal, the method comprising: internally administering to the animal an effective amount of 4-[3-[4-(6-fluoro-1,2,-benzisoxazol-3-yl)-1-piperidinyl]propoxy- ]-3-methoxy-benzoic acid or pharmaceutically-acceptable salt thereof, wherein the animal is suffering from a condition selected from the group consisting of: platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attacks, stable angina, unstable angina, thrombotic stroke, a secondary ischemic event, atrial fibrillation, thrombosis, restenosis, asthma, diabetic nephropathy, and diabetic retinopathy.

9. The method of claim 8, wherein the secondary ischemic event is selected from the group consisting of: reversible ischemic neurological deficit and intermittent claudication.

10. The method of claim 8, wherein thrombosis is clot formation associated with at least one of the following: angioplasty, cardiac surgery, or atrial fibrillation.

11. The method of claim 8, wherein the condition is restenosis as a result of treatment with a medicated device.

12. The method of claim 11, wherein the medicated device is a medicated stent.

13. A method of antagonizing a 5-HT.sub.2A receptor in an animal, the method comprising: internally administering to the animal an effective amount of 4-[3-[4-(6-fluoro-1,2,-benzisoxazol-3-yl)-1-piperidinyl]propoxy- ]-3-methoxy-benzoic acid or pharmaceutically-acceptable salt thereof; and administering to the animal at least one antithrombotic agent.

14. The method of claim 13, wherein the antithrombotic agent is selected from the group consisting of: clopidogrel bisulfate, streptokinase, alteplase, aprotinin, aspirin, and warfarin.

Details for Patent 9,987,264

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Bayer Hlthcare TRASYLOL aprotinin INJECTABLE;INJECTION 020304 001 1994-02-07   Start Trial Vanda Pharmaceuticals Inc. (Washington, DC) 2039-02-26 DISCN search
Genentech ACTIVASE alteplase VIAL; SINGLE-USE 103172 001 1987-11-13   Start Trial Vanda Pharmaceuticals Inc. (Washington, DC) 2039-02-26 RX search
Genentech ACTIVASE alteplase VIAL; SINGLE-USE 103172 002 1987-11-13   Start Trial Vanda Pharmaceuticals Inc. (Washington, DC) 2039-02-26 RX search
Genentech CATHFLO ACTIVASE alteplase VIAL 103172 003 1987-11-13   Start Trial Vanda Pharmaceuticals Inc. (Washington, DC) 2039-02-26 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Dow
Express Scripts
McKinsey
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.